Navigation Links
FDA Clears Mandometer® for the Treatment of Eating Disorders
Date:4/6/2011

NEW YORK, April 6, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration announced on March 31 that it had cleared Mandometer® for the treatment of patients with eating disorders.  

Mandometer® is an innovative device that provides biofeedback allowing individuals to monitor their rate of eating and their development of satiety during meals and in comparison to those eating normally. Once patients learn to adapt to a normal eating pattern, they are able to normalize their body weight.

The device has been shown to be effective through randomized clinical trials for the treatment of eating disorders.  Those trials have demonstrated that 75 percent of the patients treated with the Mandometer® method recover and 90 percent remain healthy over five years.

This breakthrough program was developed by Cecilia Bergh, Ph.D., and Per Sodersten, Ph.D., two researchers at the world-renowned Swedish academic health center, the Karolinska Institute in Stockholm, Sweden.  

Dr. Bergh and Dr. Sodersten founded the company Mando Group AB to establish clinics that utilize the Mandometer® method to treat eating disorders. Currently, there are already Mandometer® clinics in Sweden, in Australia and one on East 78th Street in New York.  

As a result of the issue of the FDA clearance, physicians can prescribe therapy by the Mandometer® method.  

Cecilia Bergh is CEO of Mando Group AB and is also executive director of the Mandometer®  Clinics.  Per Sodersten is professor of Behavioral Neuroendocrinology at the Karolinska Institute.

To observe the Mandometer® being used, visit: http://www.mando.se/en/Media-archive--/Information-films--/Information-films-/1.aspx

To learn more about Mandometer® go to www.mandometer.com or www.mandonyc.com.

Cecilia Bergh and Per Sodersten are available for interviews via phone or video satellite.  


'/>"/>
SOURCE Mandometer
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
2. FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids
3. FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors
4. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
5. FDA Clears a Test for Ovarian Cancer
6. Private Investment Firm Czura Thornton Today Introduces Clearstone Central Laboratories as the Newest Member of the Czura Thornton Life Science Group
7. U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States
8. FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets
9. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
10. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
11. FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
(Date:7/10/2017)... July 10, 2017  The tenth annual BioPharm ... MA at the Sheraton Boston Hotel, September ... access to global decision makers and innovative biotech startup ... science leaders during two impactful days. BioPharm America is ... with additional networking opportunities with 4,500+ life science industry ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral drug ... the Israel Securities Authority to dual-list its common stock on ... commence trading on the TASE on July 12, 2017 under ... the Company, it is expected that Oramed will be included ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 20, 2017 , ... ... Business Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 is now available for ... this effort through Guild collaborative teams. , Non-members may download the Part ...
(Date:7/20/2017)... ... July 20, 2017 , ... LINET, an international leader ... to their product line: the AVE 2 birthing bed. , Perfectly suitable for labor, ... new level of comfort and efficiency to every phase of childbirth. The AVE 2 ...
(Date:7/20/2017)... TX (PRWEB) , ... July 19, 2017 , ... At ... the availability of temporomandibular joint (TMJ) treatment and dental implants in Waco, ... TRIOS® intraoral scanner and the T-Scan™ by Tekscan®, they can capture details in the ...
(Date:7/20/2017)... ... July 19, 2017 , ... Adolfson ... healthcare project manager, Josh Christensen. As a leader in healthcare construction, AP has ... its healthcare resume in the Midwest with Josh now on board. , ...
(Date:7/20/2017)... ... ... a fun-filled, action-packed memoir of adventures. “Fidget” is the creation of published author, Carol ... summa cum laude graduate of Gardner Webb University. She has won numerous awards during ... public school, Lynn continued to pursue her love for music through playing piano, harp, ...
Breaking Medicine News(10 mins):